跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 11,291 条关于
“alternative pathway”
全部
11,291
临床试验
3,031
药物
99
机构
24
资讯
8,137
5个月前
CMS Proposes to Eliminate Alternative Payment Pathway for Breakthrough Medical Devices
去年
Iptacopan Shows Promise in Reducing Proteinuria in IgA Nephropathy
去年
Omeros Advances Zaltenibart Phase 3 Trials for PNH with Potential Superiority Over Current Treatments
去年
Omeros' Zaltenibart Receives FDA Rare Pediatric Disease Designation for C3 Glomerulopathy
去年
Ruxoprubart Shows Promising Phase II Results as Novel Monotherapy for Paroxysmal Nocturnal Hemoglobinuria
去年
Arrowhead's ARO-C3 Shows Promising Results in IgA Nephropathy Trial with 89% Reduction in C3 Levels
去年
Omeros' Zaltenibart Receives FDA Rare Pediatric Disease Designation for C3 Glomerulopathy
去年
Zaltenibart Receives FDA Rare Pediatric Disease Designation for C3 Glomerulopathy
去年
Phase 3 Trials Advance C3G Therapies for Rare Kidney Disease
去年
FDA Grants Rare Pediatric Disease Designation to Omeros' Zaltenibart for C3 Glomerulopathy
第 1 页,共 814 页
上一页
下一页